Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | CDC7 | O00311 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754735 | 0.91 | POLB (0.57) | GSK3BPOLBRAB9ATP53CYP1A2 | |
| SCHEMBL705177 | 0.82 | MAPT (0.56) | POLBRAB9ATP53CYP1A2L3MBTL1 | |
| SCHEMBL4045467 | 0.80 | CYP1A2 (0.43) | POLBRAB9ATP53CYP1A2L3MBTL1 | |
| SCHEMBL1751404 | 0.80 | CDK5 (0.51) | GSK3BCDC7POLBMAPK1ALDH1A1 | |
| SCHEMBL27598057 | 0.79 | PIN1 (0.56) | POLBRAB9ACYP1A2ALDH1A1KDM4E | |
| SCHEMBL1750038 | 0.78 | GSK3B (0.45) | GSK3BCDC7POLBRAB9ACYP1A2 | |
| SCHEMBL3425187 | 0.78 | PDPK1 (0.53) | GSK3BCYP1A2MAPK1PIM1GSK3A | |
| SCHEMBL1751136 | 0.77 | KDR (0.56) | GSK3BCDC7RAB9AAURKAGSK3A | |
| SCHEMBL2641186 | 0.76 | GSK3B (0.66) | GSK3BRAB9ATP53MAPK1FGFR1 | |
| SCHEMBL11242864 | 0.76 | PDE3B (0.61) | GSK3BCYP1A2AURKAGSK3ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063894-B1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2063894-B1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-9408845-B2 | Formulations containing pyridazine compounds | NORTHWESTERN UNIVERSITY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2592075-B1 | PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2592075-B1 | PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8933076-B2 | Pyridazine compounds, compositions and methods | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158627-B2 | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-31 | — | — | US | disclosed |
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-31 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| EP-1812408-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | Northwestern University (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050389-A2 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | GSK3B 79/4885CDC7 1358/4885POLB 2949/4885 |
| US-20090325973-A1 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS | TST, SRMS, STS | GSK3B 939/4885CDC7 1708/4885POLB 4336/4885 |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | GSK3B 11/4885CDC7 1478/4885POLB 3212/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | GSK3B 69/4885CDC7 1440/4885POLB 2947/4885 |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | GSK3B 79/4885CDC7 1358/4885POLB 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.